Periostin Exon-21 Antibody Neutralization of Triple-Negative Breast Cancer Cell-Derived Periostin Regulates Tumor-Associated Macrophage Polarization and Angiogenesis.

periostin triple-negative breast cancer tumor-associated macrophage

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
11 Oct 2021
Historique:
received: 16 08 2021
revised: 22 09 2021
accepted: 04 10 2021
entrez: 23 10 2021
pubmed: 24 10 2021
medline: 24 10 2021
Statut: epublish

Résumé

Periostin (Pn) is involved in multiple processes of cancer progression. Previously, we reported that Pn expression is correlated with mesenchymal tumor markers and poor prognosis in triple-negative breast cancer (TNBC). In the TNBC xenograft model, chemotherapy increased expression of a Pn alternative splicing variant (ASV) with exon 21, and administration of the neutralizing antibody against Pn with exon 21 (Pn-21 Ab) overcame chemoresistance with a reduction in the mesenchymal cancer cell fraction. In the present study, the role of Pn ASV with exon 21 in TNBC progression has been addressed. We first established a stable cell line carrying a fluorescence-based splicing reporter. Pn-positive TNBC has higher expression of genes related to tumor-associated macrophage (TAM) recruitment and ECM-receptor interaction than Pn-negative cells. In a xenograft model, only Pn-positive cells initiated tumor formation, and the Pn-21 Ab suppressed tumor cell growth, accompanied by decreased M2 TAM polarization and the number of tumor vessels. These data suggest that cancer cell-derived Pn ASV educates TAMs and regulates angiogenesis, which in turn establishes a microenvironmental niche that is supportive of TNBC.

Identifiants

pubmed: 34680221
pii: cancers13205072
doi: 10.3390/cancers13205072
pmc: PMC8533925
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Japan Society for the Promotion of Science
ID : JP20K07659, JP20H03181 and JP20K21385,
Organisme : Kurata Memorial Hitachi Science and Technology Foundation
ID : 1409
Organisme : Kondou Kinen Medical Foundation
ID : NA
Organisme : Nanken-Kyoten, TMDU
ID : NA

Références

Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Front Oncol. 2018 Jun 12;8:225
pubmed: 29946533
Sci Rep. 2017 Dec 7;7(1):17172
pubmed: 29215061
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
pubmed: 17671126
J Clin Invest. 2011 Oct;121(10):3797-803
pubmed: 21965336
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Cancer Treat Rev. 2018 Nov;70:178-189
pubmed: 30227299
Hypertension. 2016 Feb;67(2):356-61
pubmed: 26644236
Cancer Discov. 2018 Mar;8(3):304-319
pubmed: 29196464
Protein Sci. 2019 Nov;28(11):1947-1951
pubmed: 31441146
Cell Mol Neurobiol. 2020 Oct 3;:
pubmed: 33010018
Sci Rep. 2018 Mar 5;8(1):4013
pubmed: 29507310
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int J Dev Biol. 2011;55(7-9):861-7
pubmed: 22161841
J Cell Biol. 2012 Feb 20;196(4):395-406
pubmed: 22351925
Cell Rep. 2018 Mar 6;22(10):2530-2540
pubmed: 29514082
J Clin Invest. 2011 Jul;121(7):2750-67
pubmed: 21633166
PLoS One. 2011 Mar 21;6(3):e17911
pubmed: 21445301
Mol Cell Proteomics. 2012 Apr;11(4):M111.014647
pubmed: 22159717
J Pathol. 2016 Aug;239(4):484-95
pubmed: 27193093
Int J Oncol. 2015 Sep;47(3):840-8
pubmed: 26202679
BMC Bioinformatics. 2013 Jul 09;14:219
pubmed: 23837715
Nat Cell Biol. 2015 Feb;17(2):170-82
pubmed: 25580734
Mol Oncol. 2021 Jan;15(1):210-227
pubmed: 33124726
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690
pubmed: 27184417
Mol Cancer Res. 2016 Jan;14(1):103-13
pubmed: 26507575
Cell Death Dis. 2018 Oct 22;9(11):1082
pubmed: 30348980
Front Oncol. 2020 Jan 24;9:1512
pubmed: 32039007
Int J Oncol. 2017 Jul;51(1):104-114
pubmed: 28498427
Breast Cancer Res. 2011;13(6):227
pubmed: 22078026
PLoS One. 2013 Aug 29;8(8):e72962
pubmed: 24009721
Dev Dyn. 2018 Mar;247(3):368-381
pubmed: 28758355

Auteurs

Tatsuya Fujikawa (T)

Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.

Fumihiro Sanada (F)

Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.

Yoshiaki Taniyama (Y)

Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.
Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.

Kana Shibata (K)

Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.

Naruto Katsuragi (N)

Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.

Nobutaka Koibuchi (N)

Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.

Kaori Akazawa (K)

Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.

Yuko Kanemoto (Y)

Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.

Hidehito Kuroyanagi (H)

Department of Biochemistry, Graduate School of Medicine, University of the Ryukyu, Okinawa 903-0213, Japan.

Kenzo Shimazu (K)

Department of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.

Hiromi Rakugi (H)

Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.

Ryuichi Morishita (R)

Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan.

Classifications MeSH